Non-Alcoholic Fatty Liver Disease (NAFLD) is a significant and often overlooked health issue, particularly in the context of the global obesity epidemic. With a prevalence rate estimated at 25% worldwide, it is crucial for healthcare professionals to understand the complexities of diagnosing and treating this condition.
NAFLD is the most common chronic liver disease in Western countries, affecting up to one-third of the population. It is closely linked with metabolic syndrome, obesity, insulin resistance, and type 2 diabetes. The prevalence is increasing in parallel with the rise in obesity and type 2 diabetes, making it a significant public health concern.
Diagnosing NAFLD can be challenging due to its often asymptomatic nature. It is often identified incidentally during imaging studies or when liver enzyme levels are elevated. The gold standard for diagnosis is liver biopsy, but its invasive nature makes it unsuitable for population-wide screening. Non-invasive tools such as the NAFLD fibrosis score, FIB-4 index, and elastography are increasingly being used for risk stratification and diagnosis.
Currently, there are no approved pharmacological treatments for NAFLD. The mainstay of management is lifestyle modification, including weight loss, increased physical activity, and a healthy diet. In cases of advanced fibrosis or cirrhosis, patients may be referred for liver transplantation. Emerging therapies targeting various aspects of the disease process, such as insulin resistance, inflammation, and fibrosis, are under investigation.
NAFLD is an increasingly prevalent condition, requiring proactive identification and management by healthcare professionals. While diagnostic tools continue to evolve, treatment primarily involves lifestyle interventions. Ongoing research into pharmacological treatments promises new strategies for managing this significant public health issue.
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
TULSA Is Effective in Long-Term Prostate Cancer Control.
3.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
4.
In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".
5.
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
1.
Molecular Matching for Individualized Blood-Disorder Therapy
2.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
3.
Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship
4.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation